Name | Value |
---|---|
Revenues | 70.5M |
Cost of Revenue | 47.2M |
Gross Profit | 23.3M |
Operating Expense | 54.2M |
Operating I/L | -30.9M |
Other Income/Expense | -114.3M |
Interest Income | 5.9M |
Pretax | -145.2M |
Income Tax Expense | -10.9M |
Net Income/Loss | -128.1M |
Fulgent Genetics, Inc. provides COVID-19, molecular diagnostic, and genetic testing services globally. Their offerings include genetic tests for oncology, carrier screening, solid tumor profiling, rapid whole genome testing for children, newborn genetic analysis, and patient-initiated genetic testing. They also provide next generation sequencing, reverse transcription polymerase chain reaction-based tests, and antigen-based diagnostic tests for SARS-CoV-2. Additionally, the company offers flow cytometry, fluorescence in-situ hybridization, immunohistochemistry, cytogenetics, and molecular testing for hematopoietic and solid tumors. Fulgent Genetics serves insurance, hospitals, medical institutions, laboratories, governmental bodies, payors, municipalities, large corporations, and patients.